Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Símbolo de cotizaciónBBLG
Nombre de la empresaBone Biologics Corp
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoFrelick (Jeffrey)
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 27
Dirección2 Burlington Woods Dr Ste 100
CiudadBURLINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01803-4551
Teléfono17815524452
Sitio Webhttps://www.bonebiologics.com/
Símbolo de cotizaciónBBLG
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoFrelick (Jeffrey)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos